Evidence map›Paper›PMID 37178093›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2023

Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes.

Pavan K Bhatraju, David K Prince, Sherry Mansour, T Alp Ikizler, Edward D Siew, Vernon M Chinchilli, Amit X Garg, Alan S Go, James S Kaufman, Paul L Kimmel and 4 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors.Clinical journal of the American Society of Nephrology : CJASN · 2025
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Pavan K BhatrajuDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington. Electronic address: bhatraju@uw.edu.
David K PrinceKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Sherry MansourDivision of Nephrology, Yale University, New Haven, Connecticut.
T Alp IkizlerDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
Edward D SiewDivision of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
Vernon M ChinchilliDepartment of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, Pennsylvania.
Amit X GargDivision of Nephrology, Department of Medicine, Western University, London, Ontario, Canada.
Alan S GoDivision of Nephrology, Department of Medicine, University of California, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, California; Division of Research, Kaiser Permanente Northern California, Oakland, California.
James S KaufmanDivision of Nephrology, School of Medicine, New York University, New York, New York; Division of Nephrology, VA New York Harbor Healthcare System, New York, New York.
Paul L KimmelNational Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Steve G CocaSection of Nephrology, Department of Internal Medicine, Mount Sinai School of Medicine, New York, New York.
Chirag R ParikhDivision of Nephrology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Mark M WurfelDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington; Kidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
Jonathan HimmelfarbKidney Research Institute, Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington.
University of Washington · USVanderbilt University Medical Center · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins Medicine · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNew York University · USPennsylvania State University · USUniversity of California, San Francisco · USWestern University · CAYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Central Hub for Kidney Precision MedicineU24DK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI Jonathan Himmelfarb, Matthias Kretzler · 2022 to 2026
$21.1M
ConProject-002U2CDK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2017 to 2021
$21.0M
Study of the Care and Outcomes of REnal InsufficiencyU01DK060902 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2001 to 2025
$19.5M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Data Coordinating Center for the Natural History of AKI ConsortiumU01DK082183 · NIDDK · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI CHINCHILLI, VERNON M · 2008 to 2018
$9.7M
Genetic Determinants of Outcomes in Acute Kidney InjuryU01DK084012 · NIDDK · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, WURFEL, MARK M · 2010 to 2019
$6.2M
Progression of Acute Kidney Injury to Chronic Kidney DiseaseU01DK082185 · NIDDK · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2008 to 2017
$5.1M
Impact of Acute Kidney Injury on Kidney Disease ProgressionU01DK082192 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI IKIZLER, TALAT ALP · 2008 to 2018
$5.0M
Prospective Evaluation of Acute Kidney Injury (PEAK) CohotU01DK082223 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI GO, ALAN S · 2008 to 2018
$4.0M
A Microphysiological System for Kidney Disease Modeling and Drug Efficacy TestingUG3TR002158 · NCATS · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN · 2017 to 2018
$2.9M
Anti-Inflammatory Interventions in Maintenance Hemodialysis PatientsU01DK099923 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HIMMELFARB, JONATHAN, IKIZLER, TALAT ALP · 2013 to 2018
$2.6M
NCATS NIH HHS UG3 TR002158NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL085757NIDDK NIH HHS K23 DK088964NIDDK NIH HHS K23 DK116967NIDDK NIH HHS K24 DK092291NIDDK NIH HHS K24 DK113381NIDDK NIH HHS R01 DK098233NIDDK NIH HHS R01 DK101507NIDDK NIH HHS R01 DK133177NIDDK NIH HHS U01 DK060902NIDDK NIH HHS U01 DK082183NIDDK NIH HHS U01 DK082185NIDDK NIH HHS U01 DK082192NIDDK NIH HHS U01 DK082223NIDDK NIH HHS U01 DK084012NIDDK NIH HHS U01 DK099923NIDDK NIH HHS U01 DK106962NIDDK NIH HHS U24 DK114886NIDDK NIH HHS U2C DK114886
6 · The paper itself

Abstract

RATIONALE &

objectiveAcute kidney injury (AKI) is a heterogeneous clinical syndrome with varying causes, pathophysiology, and outcomes. We incorporated plasma and urine biomarker measurements to identify AKI subgroups (subphenotypes) more tightly linked to underlying pathophysiology and long-term clinical outcomes. STUDY

designMulticenter cohort study. SETTING &

participants769 hospitalized adults with AKI matched with 769 without AKI, enrolled from December 2009 to February 2015 in the ASSESS-AKI Study. PREDICTORS: 29 clinical, plasma, and urinary biomarker parameters used to identify AKI subphenotypes. OUTCOME: Composite of major adverse kidney events (MAKE) with a median follow-up period of 4.7 years. ANALYTICAL APPROACH: Latent class analysis (LCA) and k-means clustering were applied to 29 clinical, plasma, and urinary biomarker parameters. Associations between AKI subphenotypes and MAKE were analyzed using Kaplan-Meier curves and Cox proportional hazard models.

resultsAmong 769 AKI patients both LCA and k-means identified 2 distinct AKI subphenotypes (classes 1 and 2). The long-term risk for MAKE was higher with class 2 (adjusted HR, 1.41 [95% CI, 1.08-1.84]; P=0.01) compared with class 1, adjusting for demographics, hospital level factors, and KDIGO stage of AKI. The higher risk of MAKE among class 2 was explained by a higher risk of long-term chronic kidney disease progression and dialysis. The top variables that were different between classes 1 and 2 included plasma and urinary biomarkers of inflammation and epithelial cell injury; serum creatinine ranked 20th out of the 29 variables for differentiating classes. LIMITATIONS: A replication cohort with simultaneously collected blood and urine sampling in hospitalized adults with AKI and long-term outcomes was unavailable.

conclusionsWe identify 2 molecularly distinct AKI subphenotypes with differing risk of long-term outcomes, independent of the current criteria to risk stratify AKI. Future identification of AKI subphenotypes may facilitate linking therapies to underlying pathophysiology to prevent long-term sequalae after AKI. PLAIN-LANGUAGE SUMMARY: Acute kidney injury (AKI) occurs commonly in hospitalized patients and is associated with high morbidity and mortality. The AKI definition lumps many different types of AKI together, but subgroups of AKI may be more tightly linked to the underlying biology and clinical outcomes. We used 29 different clinical, blood, and urinary biomarkers and applied 2 different statistical algorithms to identify AKI subtypes and their association with long-term outcomes. Both clustering algorithms identified 2 AKI subtypes with different risk of chronic kidney disease, independent of the serum creatinine concentrations (the current gold standard to determine severity of AKI). Identification of AKI subtypes may facilitate linking therapies to underlying biology to prevent long-term consequences after AKI.

Indexed as

Acute Kidney InjuryRenal Insufficiency, ChronicAdultBiomarkersCohort StudiesCreatinineHumansBiomarkersCreatinineAcute kidney injurylong-termmajor adverse kidney eventssubphenotypes

Identifiers

PMID37178093
PMCPMC10523857
OpenAlexW4363675471

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.